Study provides roadmap to more personalized cancer treatment

Milo Mitchell/UCLA Jonsson Comprehensive Cancer CenterUCLA ’s Dr. Joanne Weidhaas explains her latest research, which could lead to more personalized treatments for head and neck cancer. FINDINGSResearchers have found that people with advanced head and neck squamous cell carcinoma and the KRAS-variant inherited genetic mutation have significantly improved survival when given a short course of the drug cetuximab in combination with standard chemotherapy and radiation.The study was led by UCLA Jonsson Comprehensive Cancer Center member Dr. Joanne Weidhaas in collaboration with colleagues at the NRG Oncology RTOG. They discovered that people with both head and neck squamous cell carcinoma and the KRAS-variant who were treated with standard treatment, but not with cetuximab, had a higher risk of failing treatment and developing metastatic disease, meaning the cancer spreads to distant organs and is incurable.BACKGROUNDIn 2006, researchers discovered the KRAS-variant, an inherited genetic mutation found in up to 25 percent of people with cancer. The KRAS-variant is a biomarker that disrupts a class of important regulators, called microRNAs, which were discovered in 2000. The  mutation has been shown to predict response to cancer therapy for many cancers, including head and neck cancer. It was not previously understood exactly how this biomarker worked.The current standard of care for advanced head and neck squamous cell carcinoma involves chemotherapy and radiation...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news

Related Links:

Authors: Li B, Zhu J, Meng L Abstract Actin‑like protein 8 (ACTL8) is a member of the cancer‑testis antigens (CTA) family, which is mainly localized in the cytoplasm and generally expressed in the testis. The association between ACTL8 and various types of cancer, including glioblastoma and breast cancer, has previously been demonstrated. However, whether ACTL8 is involved in the development of head and neck squamous cell carcinoma (HNSCC) remains unknown. In the present study, the expression of ACTL8 in patients with HNSCC was analyzed in The Cancer Genome Atlas (TCGA) dataset, clinical tissues and cell li...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Condition:   Head and Neck Cancer Intervention:   Radiation: Temporally Feathered Radiation Therapy (TFRT) Sponsor:   Case Comprehensive Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
PMID: 30510089 [PubMed - in process]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
PMID: 30510088 [PubMed - in process]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
rmeer Tumor cell metabolism differs from that of normal cells, conferring tumors with metabolic advantages but affording opportunities for therapeutic intervention. Accordingly, metabolism-targeting therapies have shown promise. However, drugs targeting singular metabolic pathways display limited efficacy, in part due to the tumor’s ability to compensate by using other metabolic pathways to meet energy and growth demands. Thus, it is critical to identify novel combinations of metabolism-targeting drugs to improve therapeutic efficacy in the face of compensatory cellular response mechanisms. Our lab has previo...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Advanced head and neck squamous cell carcinoma, after locoregional treatment and multiple lines of systemic therapies, represents a great challenge to overcome acquired resistance. The present clinical case illustrates a successful treatment option and is the first to describe the use of photodynamic therapy (PDT) with Redaporfin, followed by immune checkpoint inhibition with an anti-PD1 antibody. This patient presented an extensive tumor in the mouth pavement progressing after surgery, radiotherapy, and multiple lines of systemic treatment. PDT with Redaporfin achieved the destruction of all visible tumor, and the sequent...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: These data suggested that the upregulation of lncRNA LINC00473 promotes the radioresistance of HNSCC cells through activating Wnt/β-catenin signaling pathway. PMID: 30468475 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
obuhiro Hanai To investigate whether peripheral blood biomarkers predict the outcome of anti-PD-1 antibody treatment for head and neck squamous cell carcinoma (HNSCC). Patients treated with nivolumab for platinum-refractory recurrent or metastatic HNSCC were retrospectively reviewed. Fifty-three patients treated between April 2017 and March 2018 were included in the study. The median progression-free survival (PFS) and overall survival (OS) were 2.5 and 8.7 months, respectively. In the univariate analysis, performance status (PS) ≥ 3, relative neutrophil count ≥ 0.65, relative lymphocyte count ≥ 0....
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Objectives/HypothesisAnalyze the characteristics of second primary lung malignancies (SPLMs) following an index head and neck squamous cell carcinoma (HNSCC).Study DesignRetrospective cohort study.MethodsThe Surveillance, Epidemiology and End Results database was queried for all cases of HNSCC between 1973 and 2014 (N  = 101,856). This population was compared to a standard population to assess relative risk for lung cancer, calculated as the standardized incidence ratio (SIR). Patients who developed SPLMs were extracted (N = 8,116) and compared to all other cases of lung cancer (N =&thins...
Source: The Laryngoscope - Category: ENT & OMF Authors: Tags: Head and Neck Source Type: research
Publication date: 20 November 2018Source: Cell Reports, Volume 25, Issue 8Author(s): Vincent Roh, Pierre Abramowski, Agnès Hiou-Feige, Kerstin Cornils, Jean-Paul Rivals, Alexandre Zougman, Tim Aranyossy, Lars Thielecke, Zinnia Truan, Maxime Mermod, Yan Monnier, Vladimir Prassolov, Ingmar Glauche, Ali Nowrouzi, Amir Abdollahi, Boris Fehse, Christian Simon, Genrich V. TolstonogSummaryLocal recurrence after surgery for head and neck squamous cell carcinoma (HNSCC) remains a common event associated with a dismal prognosis. Improving this outcome requires a better understanding of cancer cell populations that expand from...
Source: Cell Reports - Category: Cytology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Carcinoma | Chemotherapy | Clinical Trials | Erbitux | Genetics | Head and Neck Cancer | HNSCC | Radiation Therapy | Skin Cancer | Squamous Cell Carcinoma | Study | Universities & Medical Training